Erasca, Inc. ERAS Stock Forecast
AI-powered price prediction and analysis for Erasca, Inc. ยท Updated Sep 24, 2026
See ERAS's Exact Price Target
Create a free account and follow this stock to unlock its full AI forecast โ 3 stocks free.
Sign Up Free with GooglePrice Chart
Key Statistics
About Erasca, Inc.
Erasca, Inc. (ERAS) operates in the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. .
Latest News
Where ERAS sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | Ticker | AI Signal | Market Cap | P/E |
|---|---|---|---|---|
| Erasca, Inc. | ERAS | โโ% | $5.08B | -x |
| Eli Lilly & โฆ | LLY | โโ% | $1.08T | 40.6x |
| Johnson & Johnson | JNJ | โโ% | $652.31B | 31.0x |
| Beone Medicines Ltd. | ONC | โโ% | $539.52B | -x |
| Abbvie Inc. | ABBV | โโ% | $468.43B | 74.2x |
| Merck & Co., โฆ | MRK | โโ% | $365.34B | 115.1x |
| Novartis Ag | NVS | โโ% | $272.31B | -x |
| Gsk Plc | GSK | โโ% | $214.26B | -x |
| Abbott Laboratories | ABT | โโ% | $180.26B | 28.6x |
| Pfizer Inc | PFE | โโ% | $160.62B | 37.1x |
| Vertex Pharmaceuticals Inc โฆ | VRTX | โโ% | $130.87B | 29.7x |
| Bristol Myers Squibb โฆ | BMY | โโ% | $125.63B | 13.5x |
| Regeneron Pharmaceuticals, Inc. | REGN | โโ% | $82.55B | 19.1x |
| Sanofi | SNY | โโ% | $50.80B | -x |
| Teva Pharmaceutical Industries โฆ | TEVA | โโ% | $45.46B | 64.3x |
| Alnylam Pharmaceuticals, Inc. | ALNY | โโ% | $33.40B | -x |
| Royalty Pharma Plc | RPRX | โโ% | $33.15B | 40.7x |
| Alterity Therapeutics Ltd | ATHE | โโ% | $32.40B | -x |
| Takeda Pharmaceutical Co โฆ | TAK | โโ% | $29.93B | -x |
| Zai Lab Ltd | ZLAB | โโ% | $29.68B | -x |
| Zoetis Inc. | ZTS | โโ% | $29.59B | 11.3x |
| Roivant Sciences Ltd. | ROIV | โโ% | $26.60B | -x |
| Insmed Inc | INSM | โโ% | $26.54B | -x |
| United Therapeutics Corp | UTHR | โโ% | $20.99B | 16.0x |
| Viatris Inc | VTRS | โโ% | $19.66B | -x |
| Jazz Pharmaceuticals Plc | JAZZ | โโ% | $15.34B | 16.3x |
| Ascendis Pharma A/S | ASND | โโ% | $14.30B | -x |
| Summit Therapeutics Inc. | SMMT | โโ% | $13.12B | -x |
| Bridgebio Pharma, Inc. | BBIO | โโ% | $12.96B | -x |
| Corcept Therapeutics Inc | CORT | โโ% | $12.81B | -x |
| Hutchmed (China) Ltd | HCM | โโ% | $12.13B | -x |
| Biomarin Pharmaceutical Inc | BMRN | โโ% | $11.88B | -x |
| Kiniksa Pharmaceuticals International, โฆ | KNSA | โโ% | $11.87B | -x |
| Madrigal Pharmaceuticals, Inc. | MDGL | โโ% | $11.86B | -x |
| Elanco Animal Health โฆ | ELAN | โโ% | $11.17B | -x |
| Dr Reddys Laboratories โฆ | RDY | โโ% | $10.34B | -x |
| Axsome Therapeutics, Inc. | AXSM | โโ% | $10.27B | -x |
| Arrowhead Pharmaceuticals, Inc. | ARWR | โโ% | $9.33B | -x |
| Cytokinetics Inc | CYTK | โโ% | $9.13B | -x |
| Protagonist Therapeutics, Inc | PTGX | โโ% | $8.98B | -x |
| Praxis Precision Medicines, โฆ | PRAX | โโ% | $7.88B | -x |
| Spyre Therapeutics, Inc. | SYRE | โโ% | $7.77B | -x |
| Structure Therapeutics Inc. | GPCR | โโ% | $7.71B | -x |
| Abivax S.A. | ABVX | โโ% | $7.39B | -x |
| Ionis Pharmaceuticals Inc | IONS | โโ% | $7.28B | -x |
| Alkermes Plc. | ALKS | โโ% | $6.84B | -x |
| Legend Biotech Corp | LEGN | โโ% | $6.82B | -x |
| Rhythm Pharmaceuticals, Inc. | RYTM | โโ% | $6.76B | -x |
| Biolinerx Ltd. | BLRX | โโ% | $6.68B | -x |
| Belite Bio, Inc | BLTE | โโ% | $6.67B | -x |
| Amneal Pharmaceuticals, Inc. | AMRX | โโ% | $6.32B | -x |
| Liquidia Corp | LQDA | โโ% | $6.04B | -x |
| Ligand Pharmaceuticals Inc | LGND | โโ% | $5.96B | 30.2x |
| Mirum Pharmaceuticals, Inc. | MIRM | โโ% | $5.80B | -x |
| Amarin Corp Plc\Uk | AMRN | โโ% | $5.64B | -x |
| Travere Therapeutics, Inc. | TVTX | โโ% | $5.64B | -x |
| Cogent Biosciences, Inc. | COGT | โโ% | $5.45B | -x |
| Ptc Therapeutics, Inc. | PTCT | โโ% | $5.20B | -x |
| Dianthus Therapeutics, Inc. โฆ | DNTH | โโ% | $5.07B | -x |
| Viking Therapeutics, Inc. | VKTX | โโ% | $4.86B | -x |
FAQ
-
Is Erasca, Inc. a good stock to buy?
Our AI analyzes Erasca, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
-
How accurate are Erasca, Inc. predictions?
A per-ticker accuracy statistic for ERAS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
-
How often are forecasts updated?
Erasca, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.
Ready to invest smarter?
Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Erasca, Inc.?
View full institutional-grade analysis on Intratio โAI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.